US Policy Horizon Series: From Washington to the World

The challenge we face

The global pharmaceutical landscape is undergoing a fundamental reset. Landmark US reforms, including the Inflation Reduction Act (IRA) and the proposed Most Favored Nation (MFN) pricing policy, are reshaping the economics of innovation, pricing, and access, not only within the United States but across international markets.

As governments, payers, and health technology assessment bodies adapt to these shifts, pharmaceutical companies face rising uncertainty around launch sequencing, value assessment, and return on investment. The ripple effects are being felt worldwide, influencing how markets enter, how access decisions are made, and how the burden of funding global pharmaceutical innovation is distributed.

How are we tackling this?

The US Policy Horizon Series is a fast-paced, multi-part research and policy engagement programme led by OHE, examining the shifting global landscape for pharmaceutical innovation, pricing, and equitable access.

Unlike a conventional research programme, this series is a multi-funder collaboration, bringing together a cross-sector coalition of partners and non-funding stakeholders to ensure that insights are grounded in diverse perspectives and can directly inform live policy discussions.

The series focuses on the global, ex-US perspective: articulating constructive and forward-thinking responses to the challenges and opportunities created by US pricing reforms, and providing the evidence and analysis that industry and policymakers can act on.

What topics are we exploring?

Innovation Under Pressure: Does the World Free-Ride on US Pharma Investment?

Examining the theory and evidence behind global pricing disparities, this theme explores what constitutes a fair share of global innovation investment.

Global Ripple Effects: How US Pricing Reform is Rewriting Access Strategies Worldwide

Assessing how current and proposed pricing reforms are influencing pricing strategies, market entry timing, and access outcomes around the world.

Launching into Uncertainty: Post-IRA Dynamics and Global Launch Sequencing

Examining the unintended consequences of aggressive price-linking measures on global launch behaviour and innovation timelines.

Shifting the Power Balance: What This Means for Payers, Regulators, and Pharma

Assessing how US reforms are redistributing influence in the global pharma policy landscape, elevating CMS's role, accelerating HTA convergence, etc.

Value Redefined: The New Economics of Comparative Effectiveness and Outcomes-Based Pricing

Exploring the paradox at the heart of US policy: a resistance to HTA-based value assessment at home, combined with a desire to import prices from HTA-driven markets through MFN.

Explore our latest outputs

Explore Our Full Resource Page for the Latest Developments and Insights!

From the latest updates on MFN and trade policy, to insights podcasts and more, explore our full portfolio of outputs for this programme of work.

Visit our News Feed

Most-Favoured Nation Pricing: What Do the Experts Think?

The OHE team joined ISPOR International 2026 in Philadelphia and our Insight explores some of the key themes we took away from this year’s conference.

Catch up on ISPOR

Most Favored Nation pricing: what it means for policy, patients and pharma

President Trump says the rest of the world is free-riding on American pharmaceutical prices. But what will substantial policy change mean for patients in the US and around the world?

Listen to the Podcast

The Programme in a Nutshell

Over 12-months this agile and responsive project is developing insights and expanding the evidence based through a combination of:

Flagship white papers and policy insights
Closed-door expert roundtables
Public webinars and panel events
Thought leadership and insights shared through OHE’s online forums, and media engagement